Pharmacotherapics Advice in Guidelines for COVID-19

Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and o...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2020-06, Vol.11, p.950-950
Main Authors: Chen, Zhang-Ren, Zhou, Ying, Liu, Jin, Peng, Hong-Wei, Zhou, Jian, Zhong, Hai-Li, Liu, Li-Li, Lai, Ming-Fang, Wei, Xiao-Hua, Wen, Jin-Hua
Format: Article
Language:English
Subjects:
COVID-19
guideline
Pharmacology
pharmacotherapy
pneumonia
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c462t-cf9a11f8b09bac25e3f1c1ff6397004027e72640ddfc30ebe13b9e9d5caddcb13
cites cdi_FETCH-LOGICAL-c462t-cf9a11f8b09bac25e3f1c1ff6397004027e72640ddfc30ebe13b9e9d5caddcb13
container_end_page 950
container_issue
container_start_page 950
container_title Frontiers in pharmacology
container_volume 11
creator Chen, Zhang-Ren
Zhou, Ying
Liu, Jin
Peng, Hong-Wei
Zhou, Jian
Zhong, Hai-Li
Liu, Li-Li
Lai, Ming-Fang
Wei, Xiao-Hua
Wen, Jin-Hua
description Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.
doi_str_mv 10.3389/fphar.2020.00950
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_861942a1e3ff466db1ad1d88fb9a37d8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_861942a1e3ff466db1ad1d88fb9a37d8</doaj_id><sourcerecordid>2424439410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-cf9a11f8b09bac25e3f1c1ff6397004027e72640ddfc30ebe13b9e9d5caddcb13</originalsourceid><addsrcrecordid>eNpVkUFPGzEQRq2qqCDg3hPaI5cNM7bjXV-QUFogEhI9tL1aXntMjDbrYG-Q-u9ZEorAl7E8M--z9Bj7jjATotUXYbOyecaBwwxAz-ELO0KlRK1b5F8_3A_ZaSmPMB2htVDyGzsUXDUASh0x8WuCrK1L44qy3URXqiv_HB1VcahuttFTHwcqVUi5Wtz_Xf6oUZ-wg2D7Qqdv9Zj9uf75e3Fb393fLBdXd7WTio-1C9oihrYD3VnH5yQCOgxBCT2FS-ANNVxJ8D44AdQRik6T9nNnvXcdimO23HN9so9mk-Pa5n8m2Wh2Dyk_GJvH6HoyrUItucUpI0ilfIfWo2_b0GkrGt9OrMs9a7Pt1uQdDWO2_Sfo584QV-YhPZtG8AahmQDnb4CcnrZURrOOxVHf24HSthguuZRCS4RpFPajLqdSMoX3GATzqs7s1JlXdWanblo5-_i994X_osQLMp6VLQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2424439410</pqid></control><display><type>article</type><title>Pharmacotherapics Advice in Guidelines for COVID-19</title><source>PubMed Central</source><creator>Chen, Zhang-Ren ; Zhou, Ying ; Liu, Jin ; Peng, Hong-Wei ; Zhou, Jian ; Zhong, Hai-Li ; Liu, Li-Li ; Lai, Ming-Fang ; Wei, Xiao-Hua ; Wen, Jin-Hua</creator><creatorcontrib>Chen, Zhang-Ren ; Zhou, Ying ; Liu, Jin ; Peng, Hong-Wei ; Zhou, Jian ; Zhong, Hai-Li ; Liu, Li-Li ; Lai, Ming-Fang ; Wei, Xiao-Hua ; Wen, Jin-Hua</creatorcontrib><description>Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2020.00950</identifier><identifier>PMID: 32670066</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>COVID-19 ; guideline ; Pharmacology ; pharmacotherapy ; pneumonia ; SARS-CoV-2</subject><ispartof>Frontiers in pharmacology, 2020-06, Vol.11, p.950-950</ispartof><rights>Copyright © 2020 Chen, Zhou, Liu, Peng, Zhou, Zhong, Liu, Lai, Wei and Wen.</rights><rights>Copyright © 2020 Chen, Zhou, Liu, Peng, Zhou, Zhong, Liu, Lai, Wei and Wen 2020 Chen, Zhou, Liu, Peng, Zhou, Zhong, Liu, Lai, Wei and Wen</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-cf9a11f8b09bac25e3f1c1ff6397004027e72640ddfc30ebe13b9e9d5caddcb13</citedby><cites>FETCH-LOGICAL-c462t-cf9a11f8b09bac25e3f1c1ff6397004027e72640ddfc30ebe13b9e9d5caddcb13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327107/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327107/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32670066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Zhang-Ren</creatorcontrib><creatorcontrib>Zhou, Ying</creatorcontrib><creatorcontrib>Liu, Jin</creatorcontrib><creatorcontrib>Peng, Hong-Wei</creatorcontrib><creatorcontrib>Zhou, Jian</creatorcontrib><creatorcontrib>Zhong, Hai-Li</creatorcontrib><creatorcontrib>Liu, Li-Li</creatorcontrib><creatorcontrib>Lai, Ming-Fang</creatorcontrib><creatorcontrib>Wei, Xiao-Hua</creatorcontrib><creatorcontrib>Wen, Jin-Hua</creatorcontrib><title>Pharmacotherapics Advice in Guidelines for COVID-19</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.</description><subject>COVID-19</subject><subject>guideline</subject><subject>Pharmacology</subject><subject>pharmacotherapy</subject><subject>pneumonia</subject><subject>SARS-CoV-2</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUFPGzEQRq2qqCDg3hPaI5cNM7bjXV-QUFogEhI9tL1aXntMjDbrYG-Q-u9ZEorAl7E8M--z9Bj7jjATotUXYbOyecaBwwxAz-ELO0KlRK1b5F8_3A_ZaSmPMB2htVDyGzsUXDUASh0x8WuCrK1L44qy3URXqiv_HB1VcahuttFTHwcqVUi5Wtz_Xf6oUZ-wg2D7Qqdv9Zj9uf75e3Fb393fLBdXd7WTio-1C9oihrYD3VnH5yQCOgxBCT2FS-ANNVxJ8D44AdQRik6T9nNnvXcdimO23HN9so9mk-Pa5n8m2Wh2Dyk_GJvH6HoyrUItucUpI0ilfIfWo2_b0GkrGt9OrMs9a7Pt1uQdDWO2_Sfo584QV-YhPZtG8AahmQDnb4CcnrZURrOOxVHf24HSthguuZRCS4RpFPajLqdSMoX3GATzqs7s1JlXdWanblo5-_i994X_osQLMp6VLQ</recordid><startdate>20200624</startdate><enddate>20200624</enddate><creator>Chen, Zhang-Ren</creator><creator>Zhou, Ying</creator><creator>Liu, Jin</creator><creator>Peng, Hong-Wei</creator><creator>Zhou, Jian</creator><creator>Zhong, Hai-Li</creator><creator>Liu, Li-Li</creator><creator>Lai, Ming-Fang</creator><creator>Wei, Xiao-Hua</creator><creator>Wen, Jin-Hua</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200624</creationdate><title>Pharmacotherapics Advice in Guidelines for COVID-19</title><author>Chen, Zhang-Ren ; Zhou, Ying ; Liu, Jin ; Peng, Hong-Wei ; Zhou, Jian ; Zhong, Hai-Li ; Liu, Li-Li ; Lai, Ming-Fang ; Wei, Xiao-Hua ; Wen, Jin-Hua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-cf9a11f8b09bac25e3f1c1ff6397004027e72640ddfc30ebe13b9e9d5caddcb13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>COVID-19</topic><topic>guideline</topic><topic>Pharmacology</topic><topic>pharmacotherapy</topic><topic>pneumonia</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Zhang-Ren</creatorcontrib><creatorcontrib>Zhou, Ying</creatorcontrib><creatorcontrib>Liu, Jin</creatorcontrib><creatorcontrib>Peng, Hong-Wei</creatorcontrib><creatorcontrib>Zhou, Jian</creatorcontrib><creatorcontrib>Zhong, Hai-Li</creatorcontrib><creatorcontrib>Liu, Li-Li</creatorcontrib><creatorcontrib>Lai, Ming-Fang</creatorcontrib><creatorcontrib>Wei, Xiao-Hua</creatorcontrib><creatorcontrib>Wen, Jin-Hua</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Zhang-Ren</au><au>Zhou, Ying</au><au>Liu, Jin</au><au>Peng, Hong-Wei</au><au>Zhou, Jian</au><au>Zhong, Hai-Li</au><au>Liu, Li-Li</au><au>Lai, Ming-Fang</au><au>Wei, Xiao-Hua</au><au>Wen, Jin-Hua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacotherapics Advice in Guidelines for COVID-19</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2020-06-24</date><risdate>2020</risdate><volume>11</volume><spage>950</spage><epage>950</epage><pages>950-950</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>32670066</pmid><doi>10.3389/fphar.2020.00950</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2020-06, Vol.11, p.950-950
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_861942a1e3ff466db1ad1d88fb9a37d8
source PubMed Central
subjects COVID-19
guideline
Pharmacology
pharmacotherapy
pneumonia
SARS-CoV-2
title Pharmacotherapics Advice in Guidelines for COVID-19
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T17%3A32%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacotherapics%20Advice%20in%20Guidelines%20for%20COVID-19&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Chen,%20Zhang-Ren&rft.date=2020-06-24&rft.volume=11&rft.spage=950&rft.epage=950&rft.pages=950-950&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2020.00950&rft_dat=%3Cproquest_doaj_%3E2424439410%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-cf9a11f8b09bac25e3f1c1ff6397004027e72640ddfc30ebe13b9e9d5caddcb13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2424439410&rft_id=info:pmid/32670066&rfr_iscdi=true